ONCOCARE HEALTH

Chemotherapy benefit prediction model for colon cancer
Calculate About Terms

Calculate

Important notice: the ONCOPRE algorithm is still in beta and currently undergoing validation with the help of retrospective colon cancer outcomes data from western Canada. We will not know whether these predictions are accurate until our validation process is complete, in about 3 to 6 months' time. In the interim, thank you for tryng this service. Your feedback is much appreciated and can be directed to Dr. Dimas Yusuf at dimas.yusuf@ahs.ca.

Patient demographics

TNM staging

Genetic markers of prognosis

High-risk features for stage II

High-risk features in stage II colon cancer include:

  • Bowel obstruction or perforation
  • Pre-operative CEA over 5 ng/ml
  • Indeterminate or positive margins
  • Specimen has < 13 lymph nodes
  • Lymphovascular or PN invasion
  • Poorly differentiated histology
  • Signet ring or mucinous tumor
  • T4 primary

Metastatic disease treatment

Metastatic prognostic markers

Before using ONCOPRE, you must agree to its terms of use.

Results

5-year OS for a healthy person (no cancer)

5-year OS and DFS without chemotherapy

5-year OS and DFS with chemotherapy

OS with optimal treatment

BC Cancer Agency
Cross Cancer Institute
Tom Baker Cancer Centre, Alberta Health Services
University of Alberta
University of British Columbia
University of Calgary
ONCOPRE is a healthcare quality improvement (HQI) project hosted by Oncocare Health Incorporated. Copyright © 2015–2016 the authors. All rights reserved. Using this site means you agree to its terms of use and privacy policy.